Scientific Staff

Jai Prakash

dr. Jai Prakash
Dr. Jai Prakash
Associate Professor
Biomaterials Science and Technology- Targeted Therapeutics
MIRA Institute for Biomedical Technology and Technical Medicine
Room no. ZH254
7500AE, Enschede
The Netherlands
Phone: +31534893096
Email: j.prakash@utwente.nl

Biography

Jai Prakash obtained his PhD (cum laude) in 2006 at pharmacokinetics and drug targeting from the University of Groningen on the topic “Renal-specific delivery of anti-fibrotic agents using lysozyme to treat renal fibrosis”. Thereafter, he worked as a Vice President – Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. During this period, he developed several products, which are currently in the pipeline of BiOrion. Besides that, he co-supervised PhD students on the topic “hepatic stellate cell targeting of biological and kinase inhibitors to treat liver fibrosis”. In parallel, he set up a new line of research on tumor stroma targeting to develop novel diagnostics and therapeutics for cancer. To gain new knowledge and experience in tumor stroma field, he joined the group of Prof. Arne Östman at Karolinska Institutet in Stockholm by receiving two prestigious grants Swedish Cancer Foundation grant and Marie Curie Career Integration Grant. Shortly, he became Assistant Professor in the Department of Oncology-Pathology of Karolinska Institutet. He also received a Young Researcher Swedish Research Council Project grant to develop new targeted nanotherapeutics against cancer.

In September 2012, he was appointed as Tenure-track Assistant Professor at Targeted Therapeutics section of Biomaterials, Science and Technology, located at the MIRA Institute of Biomedical Technology and Technical Medicine in the University of Twente. He has obtained several grants funded by Swedish Research council, Dutch Kidney Foundation, Phospholipid Research Centre Heidelberg, MIRA Voucher, and STW Take-off grant.

Since 2013, he also holds an Associated Scientist position in the group of Prof. Östman at the Department of Oncology-Pathology, Karolinska Institutet, Sweden.

In 2016, he has founded a UT spin-off ScarTec Therapeutics BV., which aims to develop novel therapeutic technologies for inhibiting scar formation.

Research Interests

The research goal of the Prakash lab is to design and develop new cell-specific targeting strategies to address fibrosis and fibrosis-driven cancer. Fibrosis or scarring is described as the excessive deposition of extracellular matrix (ECM) in an organ, which may lead to dysfunction of the organ and eventually death. In recent years, the contribution of fibrosis in cancer has received enormous attention due to its contribution in inducing tumor progression and metastasis. In addition, fibrotic stromal tissue hampers drug delivery to the tumors, thereby reducing therapeutic efficacy of anticancer agents.

Myofibroblasts are key cell type in organ fibrosis and tumor stroma. By means of targeting to myofibroblasts, the Prakash lab is developing novel therapeutics and diagnostics (Theranostics) for organ fibrosis and cancer. Besides myofibroblasts, macrophages are another key target cells in the tumor microenvironment. The following are the major areas in which his team is actively working on.

  • Understanding the difference between myofibroblasts’ phenotype in organ fibrosis and cancer
  • Discovering new targets in myofibroblasts in organ fibrosis and tumor stroma
  • Designing of targeting ligands e.g. peptides to therapy and drug delivery
  • Targeted delivery of nanoparticles including liposomes and polymeric nanoparticles
  • Developing 3D spheroid models to mimic tumor microenvironment for studying nanomedicine
  • Preclinical studies for targeted nanomedicine in fibrosis and tumor stroma mouse models (therapeutic efficacy and imaging)

Research Topics

1. Novel therapeutic strategies to abrogate the function of Cancer-Associated Fibroblasts (CAFs) in tumor stroma (PhD students: Praneeth Kuninty and Jonas Schnittert)

We have herein summarized the significance of CAFs in the primary tumor and at the metastatic site as well as described the therapeutic opportunities to inhibit CAF functions (Prakash J. Trends in Cancer 2016).
We have identified several key targets and developed novel therapeutics against these targets which are currently under investigation.

2. MicroRNA targets in myofibroblasts and novel delivery systems (PhD students: Praneeth Kuninty and Jonas Schnittert)

a. Novel miRNA targets in CAFs of pancreatic tumor stroma
b. Design of anti-microRNA delivery system to modulate tumor stroma  

Within the tumor microenvironment, microRNAs are dysregulated which instigate a crosstalk between tumor cells and stroma cells in favor of tumor progression. We have recently summarized miRNA targets in the tumor microenvironment (Kuninty et al, Front Oncol 2016). Furthermore, we have also identified miR-199a and 214 as key targets in CAFs of pancreatic tumor stroma and demonstrated their therapeutic significance in pancreatic tumor (Kuninty et al, Oncotarget, 2016

3. Novel 3D tumor stroma model to study nanomedicine (PhD student: Dwi L. Priwitaningrum)

a. Nanoparticle penetration in the stroma-rich 3D microtissue array consists of tumor cells and fibroblasts
b. Investigating anti-tumor effect of apoptosis-inducing PLGA nanoparticles in 3D microtissues

We have developed a 3D stroma-rich tumor spheroid platform (in collaboration of Dr. S. le Gac) which produce natural tumor barriers such as collagen that is found in human tumor tissue. Furthermore, we demonstrated that stroma present in these 3D spheroids hampers the penetration of nanoparticles. (Priwitaningrum et al, J Controlled release, 2016)

4. Tumor-associated macrophage (TAM) targeting using nanosystems (PhD student: Karin Postma, Analyst: Hetty ten Hoopen)

a. Understanding interaction of nanoparticles with different types of macrophages
b. Identifying new therapeutic targets in TAMs (M2-like phenotype) and designing novel targeting systems  

M1 and M2 macrophages

We have shown that different types of macrophages (M1 and M2) internalize nanoparticles differently depending on the protein corona formed on the nanoparticle surface. (Binnemars-Postma et al, Nanomedicine 2016)

5. Novel peptide to target tumor stromal components (Master student: Soundarya Sitaram)

6. Targeted Nanobiologicals for modulating fibrotic microenvironment (PhD student: Deby Mardhian, co-supervised by Dr. Ruchi Bansal)

7. Nano-therapeutics for the targeted modulation of inflammatory macrophages in liver fibrosis (PhD student: Dhadhang Kurniawan, co-supervised by Dr. Ruchi Bansal)

PhD Students

Current PhD students

  • Marcel Heinrich (since 2017): Modulating tumor microenvironment in glioblastoma
  • Dhadhang Kurniawan (since 2016): Nano-therapeutics for the targeted modulation of inflammatory macrophages in liver fibrosis
  • Deby Mardhian (since 2016): Targeted Nanobiologicals for modulating fibrotic microenvironment
  • Jonas Schnittert (since 2015): Pancreatic stellate cells directed therapies to treat pancreatic cancer
  • Praneeth Kuninty (since 2013): Peptide-mediated targeting strategies to treat pancreatic cancer
  • Dwi L. Priwitaningrum (since 2012): Investigating nanomedicine using advanced tumor stroma-containing models
  • Karin Postma (since 2012): Modulating tumor-associated macrophages using targeted nanomedicine 

Past PhD students

  • Dr. Rachel Hu (Thesis defense date: 29th Oct 2015, UT): Title: Core-cross-linked polymeric micelles; a versatile nanomedicine platform with broad applicability
  • Dr. Ruchi Bansal (Thesis defense date 27th Jan 2012, RuG): Title: Re-direction of interferon gamma and its signaling moiety: new options for the therapy of chronic diseases
  • Dr. Marike van Beuge (Thesis defense date 6th Jan 2012, RuG): Cell-specific delivery of protein kinase inhibitors to the fibrotic liver

Publications

2017

  1. Heinrich M*, Schnittert J*, Kuninty PR, Storm G, Prakash J. Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer (under review)
  2. Binnemars-Postma KA, Bansal R, Storm G, Prakash J. (2017) Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB J (accepted)
  3. Prakash J. and Pinzani M. (2017) Editorial: Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer. Adv Drug Del Rev. (in press)
  4. Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y. (2017) Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. (in revision)
  5. Bauesa M, Dasguptaa A, Ehlinga J, Prakash J, BoorcP, Tacke F, Kiessling F, Lammers T. (2017) Fibrosis imaging: Current concepts and future directions. Adv Drug Del Rev. (in press)
  6. Yazdani S, Bansal R, Prakash J. (2017) Drug targeting to myofibroblasts: Implications for fibrosis and cancer. (2017) Advanced Drug Delivery Reviews Jul 16. pii: S0169-409X(17)30107-2.
  7. Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song W, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J. (2017) Integrin alpha11 in regulation of myofibroblasts phenotype: Implication for fibrotic diseases. Experimental and Molecular Medicine (in press) – Nature publishing group
  8. Binnemars-Postma KA, Storm G, Prakash J. (2017) Nanomedicine strategies to target tumor-associated macrophages. International Journal of Molecular Sciences. Special issue: Tumor microenvironment and metabolism. May 4;18(5). pii: E979. doi: 10.3390/ijms18050979. 
  9. Strell C, Norberg K, Mezheyeuski A, Schnittert J, Kuninty PR, Moro C, Paulsson J, Schultz NA, Calatayud D, Löhr M, Frings O, Verbeke C, Heuchel R, Prakash J, Johansen JS, and Östman A. (2017) Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. British Journal of Cancer May 18. doi: 10.1038/bjc.2017.140.  – Nature publishing group
  10. Schnittert J, Kuninty PR, Brock R, Storm G, Prakash J. (2017) Anti-microRNA oligonucleotide delivery using peptide-based self-assembling nanocomplexes to modulate pancreatic tumor stroma myofibroblasts. Nanomedicine (Lond.) May 19. doi: 10.2217/nnm-2017-0054.
  11. Öztürk Akcora B, Storm G, Prakash J, Bansal R. (2017) Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Scientific Reports 14;7:44545. – Nature publishing group
  12. Berghuis AM, Koffijberg H, Prakash J, Terstappen LWWM, IJzerman MJ. (2017) Detecting blood based biomarkers in metastatic breast cancer: A systematic review on their current status and clinical utility. International Journal of Molecular Sciences 9;18(2). pii: E363.

    2016
  13. Bansal R, Nagorniewicz B, Prakash J. (2016) Clinical advancements in targeted therapies against liver fibrosis. Mediators of Inflammation. DOI 
  14. Van der Berg P*, Bansal R*, Daudi K, Steenbergen W#, Prakash J#. (2016) Preclinical detection of liver fibrosis using dual modality photoacoustic/ultrasound imaging. Biomedical Optics Express 14;7(12):5081-5091. DOI
  15. Priwitaningrum D, Blonde JP, van Baarlen J, Hennink WE, Storm G, Le Gac S, Prakash J. (2016) Tumor Stroma-containing 3D Spheroid Arrays: A Tool to Study Nanoparticle Penetration. J Control Release. 28;244(Pt B):257-268. DOI
  16. Binnemars-Postma KA, ten Hoopen H, Storm G, Prakash J. (2016) Differential uptake of nanoparticles by human polarized macrophages. Nanomedicine (Lond);11(22):2889-2902. DOI
  17. Hu Q, Prakash J, Rijcken C, Hennink WE, Storm G. (2016) High systemic availability of core cross-linked polymeric micelles after subcutaneous administration. International Journal of Pharmaceutics 30;514(1):112-120. DOI
  18. Hu Q, Rijcken C, van Gaal EVB, Brundel P, Prakash J, Storm G, Hennink WE, T Lammers. (2016) Core cross-linked polymeric micelles: a highly versatile platform to generate nanomedicines with divergent properties. Journal of Controlled Release pii: S0168-3659(16)30446-1. DOI
  19. Poosti F, Bansal R, Yazdani S, Prakash J, Beljaars L, van den Born J, de Borst MH, van Goor H, Hillebrands JL, Poelstra K. (2016) IFNγ peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis in unilateral ureteral obstruction in mice. Oncotarget. DOI  
  20. Prakash J. Cancer-associated fibroblasts: Perspectives in cancer therapy. (2016) Trends in Cancer 2(6): 277-9. DOI
  21. Prakash J and Pietras K. Editorial: Novel Targets and Targeting Technologies to modulate tumor microenvironment. (2016) Frontiers in Oncology, May 17;6:121. DOI
  22. Kuninty PR, Bojmar L, Tjomsland V, Larsson M, Storm G, Ostman A, Sandström P, and Prakash J. (2016) MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.  Oncotarget Feb 24. DOI
  23. Kuninty PR, Schnittert J, Storm G, Prakash J. (2016) MicroRNA targeting to modulate tumor microenvironment. Frontiers in Oncology 19;6:3. DOI

    2015
  24. Bansal R, Joop van Baarlen, Storm G, Prakash J. (2015) The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific Reports 14;5:18272.
  25. Boonstra MC, Prakash J, van de Velde CJH, Kuppen PJK, Vahrmeijer AL, Sier CFM. (2015) Stromal targets for fluorescent-guided oncologic surgery. Frontiers in Oncology 20;5:254.
  26. Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sallberg S. (2015) Hepatitis C virus nonstructural protein 3/4A dampens inflammation and contributes to slow fibrosis progression during chronic fibrosis in mice. PLoS One 10(6):e0128466
  27. Oon C.E., Strell C, Yeong KY, Ostman A, Prakash J. (2015) SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. Eur J Pharmacol S0014-2999(15)00293-9
  28. Hu Q, Rijcken CJF, Bansal R, Hennink WE, Storm G, Prakash J. (2015) Complete Regression of Breast Tumour with a Single Dose of Docetaxel-entrapped Core-Cross-linked Polymeric Micelles. Biomaterials 53:370-8.
  29. Hu Q, van Gaal EVB, Brundel P, Ippel H, Hackeng T, Rijcken CJF, Storm G, Hennink WE, Prakash J. (2015) A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. J Control Release S0168-3659(14)00820-7.
  30. Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Reker-Smit C, Klok P.A., Huitema S, Harms G, Bulthuis, M, J. van den Born, Poelstra K, van Goor H, J.L. Hillebrands. (2015) Selective delivery of PEGylated interferon gamma to renal interstitial myofibrolasts: a novel strategy for the treatment of renal fibrosis. FASEB J 29(3):1029-42.

    2014
  31. Bansal R, Prakash J, De Ruiter M, Poelstra K. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo. PLoS One. 2014 Feb 24;9(2):e89878.
  32. Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. (2014) Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo. Journal of Controlled Release 2014 Apr 10;179:18-24.

    2013
  33. van Beuge MM, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars E, Poelstra K. (2013) Extracellular matrix deposition in fibrotic mice is strongly reduced by cell-specific delivery of an ALK5-inhibitor to hepatic stellate cells. PLoS ONE;8(2):e56442.

    2012
  34. Bansal R, Tomar T, Ostman A, Poelstra K, Prakash J. (2012) Selective targeting of interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Molecular Cancer Therapeutics; 11(11):2419-28.
  35. Poosti F, Yazdani S, Dolman MEM, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, Hillebrands JH, van Goor H, de Borst MH. (2012) Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. European Journal of Pharmacology; 694(1-3):111-9.
  36. Poelstra K, Prakash J, Beljaars L. (2012) Drug targeting to the diseased liver. Journal of Controlled Release;161(2):188-97. (Review)
  37. van Beuge MM, Poelstra K, Prakash J. (2012) Specific delivery of kinase inhibitors in non-malignant and malignant diseases. Expert Opinion in Drug Delivery; 9(1):59-70. (Review)

    2011
  38. de Jong E, Winkel P, Poelstra K, Prakash J. (2011) Multiple anti-tumor effects of 15-deoxy-delta-12,14-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian carcinoma cells: novel actions on SIRT1 and HDAC. PLoS ONE; 6(9):e25192.
  39. Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. (2011) Peptide modified-albumin carrier explored as the targeted approach to deliver interferon gamma for the treatment of liver fibrosis. Molecular Pharmaceutics; 8(5):1899-909.
  40. Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J. (2011) PEGylation improves pharmacokinetic profile, liver uptake and efficacy of interferon gamma in liver fibrosis. Journal of Controlled Release; 154(3):233-40
  41. Bansal R, Prakash J, Post E, Schuppan D, Beljaars L, Poelstra K. (2011) Resolution of advanced liver fibrosis by targeted delivery of interferon-gamma to hepatic stellate cells. Hepatology; 54(2):586-96. Highlighted in Nature Reviews Gastroenterol & Hepatol 2011;8(7):359
  42. van Beuge M, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars L, Poelstra K. (2011) Increased liver uptake and antifibrotic effects of the hepatic stellate cell-targeted Rho-kinase inhibitor Y27632. Pharmaceutical Research; 28(8):2045-54.
  43. van Beuge M, Prakash J, Lacombe M, Reker-Smit C, Post E, Beljaars L, Poelstra K. (2011) Reduction of chronic liver injury by selective delivery of Rho-kinase inhibitor to hepatic stellate cells in mice. Journal of Pharmacology and Experimental Therapeutics; 337(3):628-35.

    2010
  44. Prakash J. Potential application of peptides in tumor targeting and anticancer therapeutics. Current Pharmaceutical Biotechnology 2011;12(8):1087-8
  45. Prakash J, de Jong E, Post E, Gouw ASH, Beljaars L, Poelstra K. (2010) A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGFR-binding cyclic peptide containing carrier. Journal of Controlled Release; 145:91-101.
    Highlighted as cover illustration and cover story by Prof. Kinam Park as “A new ligand for targeted drug delivery to tumor stromal cells” in Journal of Controlled Release, 2010; 145:75.
  46. Prakash J, Beljaars L, Harapanahalli AK, Zeinstra Smith M, de Jager-Krikken A, Hessing M, Steen H, Poelstra K. (2010) Targeting of anticancer drugs to tumor cells through mannose-6-phosphate/insulin-like growth factor II receptor as a new tool to treat cancer. International Journal of Cancer; 126(8):1966-81.
  47. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J, Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K, Brenner DA, Ginès P, Bataller R. (2010) Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology; 51(3):942-52.
    Highlighted in cover illustration of the issue

    2009
  48. Prakash J, Bansal R, Post E, de Jager-Krikken A, de Hooge, MH, Poelstra K. (2009) Albumin-binding and tumor vasculature determine the anti-tumor effect of 15-deoxy-delta12,14-Prostaglandin-J2 in vivo. Neoplasia; 11(12):1348-58.
  49. de Borst MH, Prakash J, Sandovici M, Klok PA, Hamming I, Kok RJ, Navis G and van Goor H. (2009) c-Jun N-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. Journal of Pharmacology and Experimental Therapeutics; 331(3):896-905.
  50. Prakash J, Beljaars L, Poelstra K. Drug screening methods for renal and liver fibrosis. Drug Screening Methods (Pre-clinical evaluation of new drugs). Editor S.K. Gupta. Pages 185-203, 2nd edition 2009. Jaypee Brothers, India.

    2008
  51. Fretz MM, Dolman ME, Lacombe M, Prakash J, Nguyen TQ, Goldschmeding R, Pato J, Storm G, Hennink WE, Kok RJ. (2008) Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release; 132(3): 200-7.
  52. Dolman MEM, Fretz MM, Lacombe M, Prakash J, Storm G, Hennink WE, Kok RJ. (2008) Inhibition of activated profibrotic signaling pathways in proximal tubular epithelial cells with targeted kinase inhibitor-lysozyme conjugates. International Journal of Pharmaceutics; 364(2):249-57.
  53. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2008) Inhibition of renal Rho kinase attenuates ischemia/reperfusion-induced injury. Journal of the American Society of Nephrology; 19(11):2086-97.
    Rank 1 journal in urology/nephrology field
  54. Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor H, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2008) Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharmaceutical Research; 25(10):2427-39.
  55. Prakash J, Poelstra K, van Goor H, Moolenaar F, Meijer DKF, Kok RJ. (2008) Novel therapeutic targets for the treatment of tubulointerstitial fibrosis. Current Signal Transduction Therapy; 3(2):97-111. (Review)

    2007 or before
  56. de Borst MH, Prakash J, Melenhorst WBWH, van den Heuvel MC, Kok RJ, van Goor H, and Navis G. (2007) Activation of c-Jun is associated with inflammation and fibrosis in human renal disease. Journal of Pathology; 213(2):219-28.Rank 2 journal of the pathology field
  57. Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers E, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. (2006) Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and pegylated drug-albumin conjugates using platinum(II) based drug linker technology. Bioconjugate Chemistry; 17(5):1246-55.
  58. Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Kéri G, Meijer DKF, Poelstra K, Kok RJ. (2006) Intracellular delivery of the p38 MAPK Inhibitor SB202190 to renal tubular cells using lysozyme: a new strategy to treat renal fibrosis. Journal of Pharmacology and Experimental Therapeutics; 319:8-19.
    Highlighted as a cover illustration of the issue
  59. Prakash J, Saluja V, Visser J, Moolenaar F, Meijer DKF, Poelstra K, Kok RJ. (2005) Bioanalysis and Pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. Journal of Chromatography B; 826(1-2):220-5.
  60. Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DKF, Moolenaar F, Poelstra K, Kok RJ. (2005) Renal-selective delivery and ACE inhibition by captopril-lysozyme conjugate. Drug Metabolism and Disposition; 33(5):683-8.
  61. Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK, Moolenaar F. (2005) Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate. Journal of Controlled Release; 3(1-3):350-1.
  62. Windt WA, Prakash J, Kok RJ, Moolenaar F, Kluppel CA, de Zeeuw D, van Dokkum RP, Henning RH. (2004) Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. Journal of the Renin-Angiotensin-Aldosterone system; 5(4):197-202.
  63. Prakash J, Velpandian T, Pande JN, Gupta SK. (2003) Serum rifampicin levels in patients with tuberculosis: effect of p-glycoprotein and CYP3A4 blockers on its absorption. Clinical Drug Investigation; 23(7):463-472.

Awards and Honors

  • Invitation from Advanced Drug Delivery Reviews to contribute a review (2017) 
  • Invitation from Trends in Cancer (Cell Press) and Journal of Controlled Release to contribute a review and research article (2016
  • Invitation from Advanced Drug Delivery Reviews (highly reputed journal, IF-15.6) to prepare a theme issue (2016)
  • Travel Award, United European Gastroenterology (UEG) conference, Oct 2016, Vienna
  • Oral Free Paper Prize (Certificate of Excellent Research) and “Travel Award”, United European Gastroenterology (UEG) conference, Oct 2015, Barcelona, Spain
  • Oral Free Paper Prize, United European Gastroenterology conference Oct 2014, Vienna
  • Innovation Grant, Dutch Kidney Foundation, The Netherlands (2014) 
  • Research Highlights published by International Innovations, Research Media, UK (2013) 
  • Honorarium, Thomson Reuters Publications, UK for contributing an industrial report (2013)
  • Young investigator grant, Swedish Research Council, Stockholm (2013)
  • Travel Award (SEK 20.000) from Radiumhemmets Forskningsfonder, Stockholm, Sweden (2011)
  • Swedish Cancer Foundation Fellow and Marie Curie Fellow, Karolinska Institutet, Sweden (2011) 
  • Honored PhD degree and Nomination for the best PhD in the Netherlands (2006) 
  • Best Poster Presentation Award, GUIDE early summer meeting, Groningen, The Netherlands (2005)
  • International travel award, International Society of Nephrology, Belgium (2005)
  • Best Poster Presentation Award at International Symposium on Recent Advances in Pharmacology conference (ISRAP), New Delhi, India (2004) 
  • Ubbo Emmius International Fellowship, University of Groningen, The Netherlands (2002)

International Activities

  • Main Theme Issue Editor, Advanced Drug Delivery Reviews, Topic: "Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer" (2016-17)
  • Review Editor, Frontiers in Molecular Biosciences – RNA section.
  • Guest Associate Editor, Frontiers in Oncology, Research Topic – Novel targets and targeting technologies to modulate tumor microenvironment. 2015-2016.
  • Scientific member of steering committee, Advanced Research in Pharmaceutical Science and Technology, NUS, Singapore – 3-5 August, 2015.
  • Guest Editor, Current Pharmaceutical Biotechnology journal, Hot topic issue (2011) “Potential applications of peptides in tumor targeting and anticancer therapeutics”
  • Guest Co-editor, Current Signal Transduction Therapy journal, special issue (2011) “Towards tailored treatment - new organ-specific drug strategies interfering in signal transduction”
  • Grant evaluator (i) Agence Nationale Recherche (ANR), France; (ii) Swedish Knut and Alice Wallenberg Foundation Fellowship; (iii) Austrian Academy of Science; (iv) COST Action (European Association for Science and Technology); (v) European Science Foundation; (vi) Research program at University of Porto, Portugal (vii) Israeli Ministry of Science, Technology & Space 
  • Reviewer for scientific journals including Science Translational Medicine, Advanced Drug Delivery Reviews, ACS Nano, Journal of Controlled Release, Journal of Pathology, PLoS Genetics, Pharmaceutical Research, Journal of Gene Therapy, PLoS ONE, European Journal of Pharmacology, Theranostics, Oncotarget, Hepatology and many others

News Highlights

Invited Lectures (selected)

  • “Modulating Tumor-Associated Macrophages: Design of M2-targeted liposomes”. Phospholipid Research Centre. Heidelberg 18-19 September 2017.
  • “Nanomedicine for fibrosis: Relaxin-coated iron oxide nanoparticles for treating liver fibrosis” CLINAM, Basel, 8-10 May 2017.
  • “Discovery of Autophagy”, Nobel Prize in Physiology and Medicine 2016, Studium Generale - Nobel lectures, University of Twente, 26 October 2016.
  • “Tumor stroma as a barrier and target: New models and targeting strategies” European Conference for Clinical Nanomedicine CLINAM 26-29 June, 2016, Basel.
  • “Novel Targets and Targeting Technologies to Challenge Fibrosis and Fibrosis-driven Cancer” European Symposium for Controlled Drug Delivery 14 April, 2016, Egmond aan Zee, Netherlands
  • “Inhibition of the STAT6 pathway as a novel strategy to inhibit tumor growth and metastasis in breast cancer“, 20th World Congress on Advances in Oncology,
8-10 October, 2015, Metropolitan Hotel, Athens, Greece.
  • “Modulation of tumor microenvironment to treat cancer”, invited by Prof. Liesbeth de Vries, University Medical Centre Groningen, The Netherlands, Aug 2015.
  • “Novel targeted medicine for modulating tumor-associated macrophages to treat cancer”, European Conference for Clinical Nanomedicine (CLINAM- 2015), Basel, Switzerland
  • “MIRA initiatives for Imaging”, Centre for Imaging and diagnostics, Mount Sinai Medical Centre, New York, June 2015.
  • “Cell-specific targeting to myofibroblasts” at Clinical Nanomedicine and Targeted therapy, European Conference for Clinical Nanomedicine (CLINAM-2014), Basel, Switzerland.
  • “Targeting tumor microenvironment: Opportunities for developing novel diagnostics and therapeutics”, Distinguished MIRA Lecture, Dec 2014, Enschede, The Netherlands.
  • “Tumor on chip: Bridging the gap for Nanomedicine”, lecture at Human Organ on chip program, Hotel Drienerburght, 2014, Enschede, The Netherlands.
  • “Fundamentals of Nanomedicine”, Guest lecture at Workshop on Nanotechnologies, Nov 2013, Enschede, The Netherlands.
  • “Targeting tumor stromal cells: a promising approach to treat cancer” at 18th World Congress on Advances in Oncology, Oct 2013, Creta Maris, Crete, Greece.
  • “Peptide-drug conjugates: New opportunities in targeted therapeutics” at Antibody-drug conjugates conference, Informa Life sciences, Jun 2013, Barcelona, Spain.
  • “Cell-specific targeted therapies: the future of medicine” at MIRA distinguished lecture series, May 2013, University of Twente, The Netherlands.
  • “Novel peptide-directed cytokines: applications in fibrosis and cancer” at Empowering antibodies conference, Jun 2012, Informa life sciences, Berlin, Germany.